How Foresite is investing its $900M fund during the ‘first era’ of AI-driven R&D

Foresite will emphasize AI and data science as it invests its new $900 million sixth fund, continuing a trend that has deepened this decade and has led up to one of the firm’s largest deals yet.

Michael Rome, a managing director at Foresite Capital, told BioCentury he believes the industry is still in the first wave of AI-guided R&D. “We’re seeing these new tools being integrated into the drug discovery toolkit, and it’s happening really fast,” he said. “But we still don’t have the fundamentals of drug discovery being replaced by AI and machine learning.”...